TY - JOUR
AU - 
AB - Activating mutations of codons 12 and 13 of the KRAS gene occur frequently in colorectal carcinomas. Clinical trials have shown patients with metastatic colorectal cancer benefit from treatment with tyrosine kinase inhibitors, eg. Vectibix (panitumumab), used to block EGFR overexpression if point mutations in codons 12 or 13 of the KRAS gene are absent. The DxS KRAS mutation kit, mandated by Health Canada as a companion diagnostic, doubled in price to $200-$500 per patient tested, making it less attractive for use by clinical laboratories. Using 25 cases of colorectal cancer previously analyzed by an external laboratory, we validated and compared DxS (Amplification Refractory) and a less costly method, SNaPshot (Primer Extension), for KRAS mutation analysis as well as two extraction methods, Qiagen FFPE and PicoPure. We demonstrated that DNA purified using the Qiagen FFPE kit produced more consistent results. KRAS mutation status was obtained for all samples assayed and were compared with results from the external laboratory. Both DxS and SNaPshot met the required analytic sensitivity of 1% mutant to wild-type background. One sample was discordant by both assays with those previously reported due to either the assays or sampling from a different location in the tumour tissue. SNaPshot 
TI - Optimization of a Molecular Genetic Assay for the Sensitive Detection of KRAS Mutations in Colorectal Carcinoma
JO - Dalhousie Medical Journal
DO - 10.15273/dmj.vol40no1.3790
DA - 2013-11-10
UR - https://www.deepdyve.com/lp/unpaywall/optimization-of-a-molecular-genetic-assay-for-the-sensitive-detection-ee9StkPA4o
DP - DeepDyve
ER -